Cingulate INC DEF 14A proxy statements

Cingulate Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders to be held on July 9, 2026.

Cingulate Inc. calls a Special Meeting to approve the conversion of preferred stock and exercise of warrants from a recent $12 million private placement, crucial for Nasdaq compliance and future capital.

Cingulate Inc. is calling a special stockholder meeting to approve the issuance of over 20% of its common stock to Lincoln Park Capital Fund, LLC, enabling access to up to $25 million in capital.

Cingulate Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Cingulate Inc. is asking stockholders to approve a reverse stock split and an amendment to its equity incentive plan at the upcoming annual meeting.

Cingulate Inc. has adjourned its Special Meeting of Stockholders to August 28, 2024, due to the absence of a quorum, urging stockholders to vote on the proposals.

Cingulate Inc. is holding a special meeting of stockholders to approve the issuance of shares underlying certain warrants, aiming to comply with Nasdaq Listing Rule 5635(d).

Cingulate Inc. supplements its proxy statement with details about retaining Alliance Advisors as a proxy solicitation agent for its upcoming special meeting.

Cingulate Inc. is asking stockholders to approve a reverse stock split, ranging from 1:2 to 1:15, to regain compliance with Nasdaq's minimum bid price requirement and avoid potential delisting.

Cingulate Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Cingulate Inc. is holding its annual meeting on June 11, 2024, to vote on director elections, ratify the appointment of KPMG LLP as its independent accounting firm, and approve an amendment to the company's equity incentive plan.